Premium Reports
Precision Medicine Provider Validations 2018

Precision Medicine Provider Validations 2018
The Voice of the Provider - Report 2 of 2

Authored by: Kody Hansen and Alex McIntosh November 8, 2018 | Read Time: 5  minutes

Current Time Inside Cache Tag Helper: 10/31/2020 3:56:15 PM and Model.reportId = 1363

The transformative promise of precision medicine is often cited by healthcare industry leaders (both providers and vendors) as the driving reason why healthcare organizations need to begin their own clinical genomics programs. But with high barriers to entry, questions remain about whether precision medicine technology has reached a point where pioneering provider organizations have been able to realize a return on their investments. In KLAS’ previous report on the subject, vendors weighed in on the functionalities they offer; in this report, providers share their perspective on the vendors they use. While performance data on individual vendors is not available in this report due to the early nature of this market, KLAS has aggregated the results as a measure of overall performance.

Healthcare Providers,
Want to see full details?

Not a Provider, contact us for pricing details.

Current Time Inside Cache Tag Helper: 10/31/2020 3:56:15 PM and Model.reportId = 1363

Key Findings

  1. Provider-Reported Solution Capabilities
  2. Best Practices: Don’t Underestimate the Efforts Needed
  3. Providers Extremely Skeptical about the EMR’s Role in Precision Medicine
  4. The Business Case for Precision Medicine
  5. A Starting Point: Satisfaction with Vendors High among Pioneering Organizations
 Download Report Brief  Download Full Report

This material is copyrighted. Any organization gaining unauthorized access to this report will be liable to compensate KLAS for the full retail price. Please see the KLAS DATA USE POLICY for information regarding use of this report. © 2020 KLAS Research, LLC. All Rights Reserved. NOTE: Performance scores may change significantly when including newly interviewed provider organizations, especially when added to a smaller sample size like in emerging markets with a small number of live clients. The findings presented are not meant to be conclusive data for an entire client base.